- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05656521
101-PGC-005 for the Treatment of COVID-19
A Prospective, Randomized, Comparative, Multi-centric, Adaptive Design Clinical Study to Evaluate Efficacy, Safety, and Tolerability of 101-PGC-005 ('005) for the Treatment of Moderate Corona Virus Disease (COVID-19) Patients
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
The study is planned as an adaptive Phase II/III clinical study to allow for seamless transition to Phase III after completion of Phase II. The study will begin as initially only a Phase II to evaluate and compare the efficacy, safety, and tolerability of bolus injection of 20 mg '005 vs dexamethasone 6 mg injection for the treatment of COVID-19.
The treatment period with the investigational product in the test group will be 3 consecutive days. However, in the comparator group, the patient will be allowed to take 6 mg dexamethasone daily for the duration of their treatment, based on the investigator's clinical judgement for a total of not more than 10 days or until the time of discharge, whichever is earlier. All patients in either test or control groups will be allowed to take other concomitant SOC as per the prescribed schedule for entire duration of the study, as applicable.
Study Type
Enrollment (Actual)
Phase
- Phase 2
Contacts and Locations
Study Locations
-
-
Andhra Pradesh
-
Srikakulam, Andhra Pradesh, India
- Government Medical College & General Hospital
-
-
Karnataka
-
Bangalore, Karnataka, India
- Victoria Hospital Bangalore
-
-
Maharashtra
-
Pune, Maharashtra, India
- Sangvi Multispeciality Hospital
-
-
Rajastan
-
Jaipur, Rajastan, India
- SMS Medical College and Attached Hospitals
-
-
Uttar Pradesh
-
Ghāziābād, Uttar Pradesh, India
- Santosh Medical College and Hospital
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Male or female patients of age 18 to 65 years (both inclusive) who have been hospitalized for treatment of moderate COVID-19 disease.
Patients with 'moderate' COVID-19 disease severity, as defined by Comprehensive Guidelines for Management of COVID-19 patients, Directorate General of Health Services, MoHFW, GOI; AND having any of the following symptoms and signs prior to randomization:
- Fever, cough, with or without sore throat/throat irritation, body ache/headache, malaise/weakness, diarrhoea or gastrointestinal upset, with or without anorexia/nausea/vomiting, with or without loss of smell and/or taste, shortness of breath/breathlessness and difficulty in breathing
- Respiratory rate of >24 to <30 breaths/min,
- SpO2: 90 - 93% on room air
- Patients with positive RT-PCR test for SARS-CoV-2 in nasopharyngeal or oropharyngeal swabs (sample collected within 7 days prior to randomization)
- Elevated CRP, ESR or Ferritin levels
- In case of female patients of child-bearing potential, a negative urine pregnancy test prior to beginning the therapy.
- Willing to sign voluntary informed consent for participation in the study and willing to adhere to all protocol procedures. In case the subject is unable to provide informed consent than the same should be obtained from legally acceptable representative (LAR).
Exclusion Criteria:
Patients with 'mild' or 'severe' COVID-19 disease severity, as defined by latest Comprehensive Guidelines for Management of COVID-19 patients, Directorate General of Health Services, MoHFW, GOI at the time of randomization. This includes any one or more of the following
- Peripheral Blood oxygen saturation ≥94% or <90%
- Respiratory Rate or <24 or ≥30 breaths per minute
- First positive RT-PCR more than 7 days prior to treatment administration
- Patients with evidence of other serious infectious, malignant, autoimmune, kidney, hepatic, cardiovascular or other systemic disease and/or laboratory abnormality, which, in the opinion of the investigator, prevent the patient from participating in the study
- Subjects with Chronic liver disease (Child Pugh class B or C) and chronic renal disease (GFR<30ml/min).
- Renal dysfunction [Serum Creatinine > 2.5 times of ULN or calculated creatinine clearance < 30ml/min], Liver Dysfunction [Total Bilirubin > 3times ULN & AST/ALT > 5times ULN].
- Chronic systemic glucocorticoid treatment or any immunosuppressive treatment
- History of human immunodeficiency virus (HIV) or active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV)
- Pregnant and Lactating patients.
- Patients who require IL-6 inhibitors for management of inflammation at the time of study entry.
- Subject has a psychiatric disease that is not well controlled where controlled is defined as: stable on a regimen for more than one year.
- Hospital discharge is anticipated in ≤ 24 hours or anticipated transfer to another hospital which is not a study site within 72 hours.
- Patients that are currently or have participated in such studies participating in other clinical studies with investigational drug, biological agent or device within 1 month or within 5 half-lives (of the drug/biologic) prior to randomization (whichever is longer).
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: '005 Treatment Arm
'005 IV 20 mg + Standard of care
|
'005 is a targeted prodrug of dexamethasone that binds to activated macrophages.
|
Active Comparator: Dexamethasone Treatment Arm
Dexamethasone 6 mg + Standard of care
|
Dexamethasone is a glucocorticoid commonly prescribed to treat inflammation.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Clinical Improvement
Time Frame: Baseline through Days 10, 14, 28
|
Clinical improvement or shift in WHO 11-point ordinal scale rating
|
Baseline through Days 10, 14, 28
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Reduction in Symptoms
Time Frame: Baseline through Days 10, 14, 28
|
Improvement in COVID-19 Symptoms such as fever, heart rate, and oxygen saturation
|
Baseline through Days 10, 14, 28
|
Reduction in Inflammatory Markers
Time Frame: Baseline and Days 14, 28
|
Improvement in biochemical inflammatory markers such as CRP, Neutrophil-Lymphocyte (N/L) ratio, D-Dimer, Sr. Ferritin, IL-6, and TNF-α
|
Baseline and Days 14, 28
|
Reduction in Oxygen Supplementation
Time Frame: 28 days
|
28 days
|
|
Discharge Rate from hospital
Time Frame: 28 days
|
28 days
|
|
Reduction in ICU Admission/Mechanical Ventilation
Time Frame: 28 days
|
28 days
|
|
Reduction in time to Respiratory Viral Clearance
Time Frame: Days 3, 7, 10, 14
|
Days 3, 7, 10, 14
|
|
Reduction in Lung Injury on Chest HRCT
Time Frame: Baseline and 14, 28 Days
|
Baseline and 14, 28 Days
|
|
Reduction in All-cause Mortality
Time Frame: 28 days
|
28 days
|
Collaborators and Investigators
Sponsor
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Coronavirus Infections
- Coronaviridae Infections
- Nidovirales Infections
- RNA Virus Infections
- Virus Diseases
- Infections
- Respiratory Tract Infections
- Respiratory Tract Diseases
- Pneumonia, Viral
- Pneumonia
- Lung Diseases
- COVID-19
- Physiological Effects of Drugs
- Autonomic Agents
- Peripheral Nervous System Agents
- Anti-Inflammatory Agents
- Antineoplastic Agents
- Antiemetics
- Gastrointestinal Agents
- Glucocorticoids
- Hormones
- Hormones, Hormone Substitutes, and Hormone Antagonists
- Antineoplastic Agents, Hormonal
- Dexamethasone
Other Study ID Numbers
- PGC-005-IN-101-2
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on COVID-19
-
University of Roma La SapienzaQueen Mary University of London; Università degli studi di Roma Foro Italico; Bios Prevention SrlCompletedPost Acute Sequelae of COVID-19 | Post COVID-19 Condition | Long-COVID | Chronic COVID-19 SyndromeItaly
-
Yang I. PachankisActive, not recruitingCOVID-19 Respiratory Infection | COVID-19 Stress Syndrome | COVID-19 Vaccine Adverse Reaction | COVID-19-Associated Thromboembolism | COVID-19 Post-Intensive Care Syndrome | COVID-19-Associated StrokeChina
-
Massachusetts General HospitalRecruitingPost Acute COVID-19 Syndrome | Long COVID | Post Acute Sequelae of COVID-19 | Long COVID-19United States
-
Indonesia UniversityRecruitingPost-COVID-19 Syndrome | Long COVID | Post COVID-19 Condition | Post-COVID Syndrome | Long COVID-19Indonesia
-
Erasmus Medical CenterDa Vinci Clinic; HGC RijswijkNot yet recruitingPost-COVID-19 Syndrome | Long COVID | Long Covid19 | Post COVID-19 Condition | Post-COVID Syndrome | Post COVID-19 Condition, Unspecified | Post-COVID ConditionNetherlands
-
Dr. Soetomo General HospitalIndonesia-MoH; Universitas Airlangga; Biotis Pharmaceuticals, IndonesiaRecruitingCOVID-19 Pandemic | COVID-19 Vaccines | COVID-19 Virus DiseaseIndonesia
-
University of Witten/HerdeckeInstitut für Rehabilitationsforschung NorderneyCompletedPost-COVID-19 Syndrome | Long-COVID-19 SyndromeGermany
-
Jonathann Kuo, MDActive, not recruitingSARS-CoV2 Infection | Post-COVID-19 Syndrome | Dysautonomia | Post Acute COVID-19 Syndrome | Long COVID | Long Covid19 | COVID-19 Recurrent | Post-Acute COVID-19 | Post-Acute COVID-19 Infection | Post Acute Sequelae of COVID-19 | Dysautonomia Like Disorder | Dysautonomia Orthostatic Hypotension Syndrome | Post... and other conditionsUnited States
-
University Hospital, Ioannina1st Division of Internal Medicine, University Hospital of IoanninaRecruitingCOVID-19 Pneumonia | COVID-19 Respiratory Infection | COVID-19 Pandemic | COVID-19 Acute Respiratory Distress Syndrome | COVID-19-Associated Pneumonia | COVID 19 Associated Coagulopathy | COVID-19 (Coronavirus Disease 2019) | COVID-19-Associated ThromboembolismGreece
Clinical Trials on 101-PGC-005
-
101 TherapeuticsActive, not recruitingVirus Diseases | COVID-19 | Infectious Disease | Glucocorticoids ToxicityIndia
-
101 TherapeuticsTerminated
-
Longbio PharmaRecruitingParoxysmal Nocturnal Hemoglobinuria (PNH)China
-
Seelos Therapeutics, Inc.WithdrawnAlzheimer's DiseaseAustralia
-
Eleven BiotherapeuticsCompleted
-
AbbVieTerminated
-
BJ Bioscience, Inc.Active, not recruitingAdvanced Solid Tumor or LymphomaUnited States
-
Seelos Therapeutics, Inc.TerminatedSpinocerebellar Ataxia Type 3United States, Spain, Korea, Republic of, Australia, United Kingdom, Brazil, Germany, Portugal
-
Xenon Pharmaceuticals Inc.Completed
-
Sigilon Therapeutics, Inc.WithdrawnMPS I | MPS1-S | MPS1-HSBrazil, United Kingdom